$0.63
2.26% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US04746L1044
Symbol
ATHA
Sector
Industry

Athira Pharma Inc Stock price

$0.63
+0.16 34.14% 1M
-2.01 76.23% 6M
-1.80 74.18% YTD
-0.90 58.99% 1Y
-13.83 95.66% 3Y
-16.37 96.31% 5Y
-16.37 96.31% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.01 2.26%
ISIN
US04746L1044
Symbol
ATHA
Sector
Industry

Key metrics

Market capitalization $24.26m
Enterprise Value $-51.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.53
P/B ratio (TTM) P/B ratio 0.42
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-111.85m
Free Cash Flow (TTM) Free Cash Flow $-97.48m
Cash position $77.23m
EPS (TTM) EPS $-2.85
P/E forward negative
Short interest 5.76%
Show more

Is Athira Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Athira Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Athira Pharma Inc forecast:

5x Hold
100%

Analyst Opinions

5 Analysts have issued a Athira Pharma Inc forecast:

Hold
100%

Financial data from Athira Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.97 0.97
13% 13%
-
-0.97 -0.97
13% 13%
-
- Selling and Administrative Expenses 26 26
21% 21%
-
- Research and Development Expense 84 84
0% 0%
-
-111 -111
6% 6%
-
- Depreciation and Amortization 0.97 0.97
13% 13%
-
EBIT (Operating Income) EBIT -112 -112
6% 6%
-
Net Profit -109 -109
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Athira Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Athira Pharma Inc Stock News

Neutral
GlobeNewsWire
19 days ago
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
Negative
GeekWire
2 months ago
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
Neutral
GlobeNewsWire
2 months ago
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
More Athira Pharma Inc News

Company Profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.

Head office United States
CEO Mark Litton
Employees 67
Founded 2011
Website www.athira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today